BCPC vs IONS Comparison

Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, agricultural, and medical sterilization industries. The segments include 1) Human Nutrition and Health segment provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. 2) The Animal Nutrition and Health segment provide nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride. 3) The Specialty Products segment includes re-packaging and distributing a number of performance gases and chemicals for various uses, notably ethylene oxide, propylene oxide, and ammonia.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.